Advertisement
Singapore markets closed

  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     

  • Nikkei

    38,814.56
    +94.09 (+0.24%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • Bitcoin USD

    66,046.67
    +43.19 (+0.07%)
     

  • CMC Crypto 200

    1,403.34
    -14.54 (-1.03%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • Dow

    38,589.16
    -57.94 (-0.15%)
     

  • Nasdaq

    17,688.88
    +21.32 (+0.12%)
     

  • Gold

    2,348.40
    +30.40 (+1.31%)
     

  • Crude Oil

    78.49
    -0.13 (-0.17%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     

  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     

  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

PR Newswire
·2-min read

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2024 on Tuesday, May 28, 2024, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 30, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

ADVERTISEMENT

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

CONTACTS:

United States
John Lacey
BioLineRx
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2024-results-on-may-28-2024-302151919.html

SOURCE BioLineRx